These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 27285067)

  • 1. Targeting bacterial topoisomerases: how to counter mechanisms of resistance.
    Tse-Dinh YC
    Future Med Chem; 2016 Jun; 8(10):1085-100. PubMed ID: 27285067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA Topoisomerases as Targets for Antibacterial Agents.
    Hiasa H
    Methods Mol Biol; 2018; 1703():47-62. PubMed ID: 29177732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topoisomerase as target for antibacterial and anticancer drug discovery.
    Kathiravan MK; Khilare MM; Nikoomanesh K; Chothe AS; Jain KS
    J Enzyme Inhib Med Chem; 2013 Jun; 28(3):419-35. PubMed ID: 22380774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and characterization of novel tetrahydropyran-based bacterial topoisomerase inhibitors with potent anti-gram-positive activity.
    Surivet JP; Zumbrunn C; Rueedi G; Hubschwerlen C; Bur D; Bruyère T; Locher H; Ritz D; Keck W; Seiler P; Kohl C; Gauvin JC; Mirre A; Kaegi V; Dos Santos M; Gaertner M; Delers J; Enderlin-Paput M; Boehme M
    J Med Chem; 2013 Sep; 56(18):7396-415. PubMed ID: 23968485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs.
    Pommier Y; Leo E; Zhang H; Marchand C
    Chem Biol; 2010 May; 17(5):421-33. PubMed ID: 20534341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting bacterial topoisomerase I to meet the challenge of finding new antibiotics.
    Tse-Dinh YC
    Future Med Chem; 2015; 7(4):459-71. PubMed ID: 25875873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bacterial DNA replication enzymes as targets for antibacterial drug discovery.
    Sanyal G; Doig P
    Expert Opin Drug Discov; 2012 Apr; 7(4):327-39. PubMed ID: 22458504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring DNA topoisomerases as targets of novel therapeutic agents in the treatment of infectious diseases.
    Tse-Dinh YC
    Infect Disord Drug Targets; 2007 Mar; 7(1):3-9. PubMed ID: 17346206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Structural Features of Novel Bacterial Topoisomerase Inhibitors That Define Their Activity on Topoisomerase IV.
    Kokot M; Anderluh M; Hrast M; Minovski N
    J Med Chem; 2022 May; 65(9):6431-6440. PubMed ID: 35503563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New developments in non-quinolone-based antibiotics for the inhibiton of bacterial gyrase and topoisomerase IV.
    Badshah SL; Ullah A
    Eur J Med Chem; 2018 May; 152():393-400. PubMed ID: 29751233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Bacterial type II topoisomerases as targets for antibacterial drugs].
    Pietrusiński M; Staczek P
    Postepy Biochem; 2006; 52(3):271-82. PubMed ID: 17201062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topoisomerases: Resistance versus Sensitivity, How Far We Can Go?
    Bansal S; Bajaj P; Pandey S; Tandon V
    Med Res Rev; 2017 Mar; 37(2):404-438. PubMed ID: 27687257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topoisomerases as anticancer targets.
    Delgado JL; Hsieh CM; Chan NL; Hiasa H
    Biochem J; 2018 Jan; 475(2):373-398. PubMed ID: 29363591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure activity relationship of substituted 1,5-naphthyridine analogs of oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents (Part-4).
    Singh SB; Kaelin DE; Wu J; Miesel L; Tan CM; Meinke PT; Olsen DB; Lagrutta A; Wei C; Peng X; Wang X; Fukuda H; Kishii R; Takei M; Shibata T; Ohata K; Takano H; Kurasaki H; Takeuchi T; Nishimura A; Fukuda Y
    Bioorg Med Chem Lett; 2015 Jun; 25(11):2409-15. PubMed ID: 25911300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological evaluation of benzothiazole ethyl urea inhibitors of bacterial type II topoisomerases.
    Stokes NR; Thomaides-Brears HB; Barker S; Bennett JM; Berry J; Collins I; Czaplewski LG; Gamble V; Lancett P; Logan A; Lunniss CJ; Peasley H; Pommier S; Price D; Smee C; Haydon DJ
    Antimicrob Agents Chemother; 2013 Dec; 57(12):5977-86. PubMed ID: 24041906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drugging topoisomerases: lessons and challenges.
    Pommier Y
    ACS Chem Biol; 2013 Jan; 8(1):82-95. PubMed ID: 23259582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topoisomerase inhibition, nucleolytic and electrolytic contribution on DNA binding activity exerted by biological active analogue of coordination compounds.
    Patel MN; Bhatt BS; Dosi PA
    Appl Biochem Biotechnol; 2012 Apr; 166(8):1949-68. PubMed ID: 22391694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploitation of a novel allosteric binding region in DNA gyrase and its implications for antibacterial drug discovery.
    M Orritt K; Maxwell A; Wg Fishwick C; J McPhillie M
    Future Med Chem; 2021 Dec; 13(24):2125-2127. PubMed ID: 34605249
    [No Abstract]   [Full Text] [Related]  

  • 19. Recent advances in bacterial topoisomerase inhibitors.
    Bradbury BJ; Pucci MJ
    Curr Opin Pharmacol; 2008 Oct; 8(5):574-81. PubMed ID: 18555745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel compounds targeting bacterial DNA topoisomerase/DNA gyrase.
    Ehmann DE; Lahiri SD
    Curr Opin Pharmacol; 2014 Oct; 18():76-83. PubMed ID: 25271174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.